EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy

Betül Altunay, Laura Schäfer, Agnieszka Morgenroth, Quim Peña, Twan Lammers, Matthias Saar, Felix M Mottaghy, Susanne Lütje

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.270317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Betül Altunay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PSMA-targeted radiopharmaceutical therapy (RPT) is a standard treatment for metastatic castration-resistant prostate cancer (PCa), exploiting PSMA overexpression to deliver cytotoxic radiation. Treatment with the β-emitter [177Lu]Lu-PSMA-617, approved in 2022, has been associated with prolonged progression-free and overall survival in patients with PCa. However, resistance and heterogeneous patient responses limit its efficacy. Although immunotherapy is effective in several malignancies, PCa's immunosuppressive microenvironment often reduces its impact. Combining targeted RPT with immune checkpoint inhibitors, particularly programmed cell death protein 1 and programmed cell death ligand 1 inhibitors, may enhance antitumor responses. This review explores the rationale behind this combination, evaluates preclinical and clinical evidence, and discusses future directions for integrating immune checkpoint blockade with targeted RPT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyRadiopharmaceuticalsGlutamate Carboxypeptidase IIAntigens, SurfaceMolecular Targeted TherapyHumansCombined Modality TherapyProstatic Neoplasms, Castration-ResistantMaleAnimals

Stichwörter der Autor:innen

PSMA-targeted radiopharmaceutical therapyimmune checkpoint inhibitionimmunotherapyprostate cancer

Substanzen

RadiopharmaceuticalsGlutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.
  • Institute for Experimental Molecular Imaging, University Hospital Aachen, Aachen, Germany.
  • Center for Integrated Oncology, University Hospital Aachen, Aachen, Germany.
  • Department of Urology and Pediatric Urology, University Hospital Aachen, Aachen, Germany; and.
  • Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany; sluetje@ukaachen.de.

Zitieren

APA

Altunay, B., Schäfer, L., Morgenroth, A., Peña, Q., Lammers, T., Saar, M., Mottaghy, F. M., & Lütje, S. (2025). Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270317

Vancouver

Altunay B, Schäfer L, Morgenroth A, Peña Q, Lammers T, Saar M, et al. Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270317

BibTeX
@article{Altunay2025,
  author = {Altunay, Betül and Schäfer, Laura and Morgenroth, Agnieszka and Peña, Quim and Lammers, Twan and Saar, Matthias and Mottaghy, Felix M and Lütje, Susanne},
  title = {Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.270317}
}
Kostenlos starten →